DiaSorin S.p.A. Completes Acquisition of the Focus Diagnostics' Molecular and Immunoassay Product Business from Quest Diagnostics
Quest Diagnostics | May 13, 2016
DiaSorin S.p.A. (FTSE Italy: DIA) today announced the completion of the transaction to acquire the Focus Diagnostics' immunodiagnostic and molecular diagnostic products business ("Focus") from Quest Diagnostics (NYSE: DGX), initiated with a binding purchase agreement signed on March 29, 2016.